Why the study?
Antiretroviral therapy has increased life expectancy in HIV-infected patients, making cardiovascular disease a leading cause of mortality and disability.
Answers are grounded in this paper and cite their sources.
Cardiovascular diseases have become a leading cause of mortality and disability in HIV patients, driven by both virus-mediated mechanisms and antiretroviral therapy.
The review presents the rationale for studying cardiovascular disease in HIV-infected patients, as well as the importance of specific therapy. The embrace of this problem is due the widespread use of antiretroviral therapy in the world over the past 20 years has led to an increase in the life expectancy of HIV patients, while cardiovascular diseases have become a mortality and disability leader. The review presents the most frequently reported cardiovascular pathology and cardiac complications in HIV patients that occur both against the background of virus-mediated action and as a result of antiretroviral therapy. Some pathogenetic mechanisms of HIV influence on cardiomyocytes and the extracellular matrix have been demonstrated, resulting in early heart failure and pulmonary hypertension. Information is given on the role of statins in the management of HIV patients with the clinically significant atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Козиолова et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: